{"id":36769,"date":"2021-10-26T12:19:42","date_gmt":"2021-10-26T11:19:42","guid":{"rendered":"https:\/\/www.biotechpharmasummit.com\/?page_id=36769"},"modified":"2021-10-26T12:22:50","modified_gmt":"2021-10-26T11:22:50","slug":"philip-leighton","status":"publish","type":"page","link":"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/philip-leighton\/","title":{"rendered":"Philip Leighton"},"content":{"rendered":"<div class=\"vgblk-rw-wrapper limit-wrapper\">\n\n\t<h2>Dr. Philip Leighton<\/h2>\n<h4>Sr. Director, Molecular Biology at Ligand Pharmaceuticals Incorporated<\/h4>\n\t<p>Dr. Leighton is Senior Director of Molecular Biology at Ligand Pharmaceuticals in Emeryville, CA.\u00a0 He received his Ph.D in Molecular Biology from Princeton University, followed by post-doctoral studies at the University of California, San Francisco.\u00a0 At Ligand, he is responsible for the development and validation of the OmniChicken<sup>\u00ae<\/sup>\u00a0portion of the OmniAb<sup>\u00ae<\/sup>\u00a0platform for the production of human antibodies in transgenic chickens.\u00a0 In addition to OmniChickens expressing normal human antibodies, he has more recently developed OmniClic<sup>\u00ae<\/sup>\u00a0chickens expressing a common light chain for bispecific antibody discovery.\u00a0 Currently under development are OmniDab<sup>TM <\/sup>chickens expressing single domain antibodies, and the OmniTaur<sup>TM <\/sup> platform for heavy chains with ultralong CDR-H3s.\u00a0 OmniChickens are currently being used in a number of programs by pharmaceutical industry partners.<\/p>\n\t\t\t\t\t\t\t<img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2021\/10\/Phil_Leighton_ligand_BioTech_Pharma_Summit_2021_gallery.jpg\" alt=\"Contemporary Headshot and Portrait Studio in Emeryville, CA\n1501 Powell St, Suite N, Emeryville, CA | 510-560-5480  \ninfo@bayareaheadshotcompany.com\nSan Francisco Bay Area Personal Branding, Business Portraits and Headshots\n\u00a9 2017 Aida Jones, LLC. All Right Reserved.\" itemprop=\"image\" height=\"1224\" width=\"820\" title=\"Ligand North Emeryville, CA\" onerror=\"this.style.display='none'\"  sizes=\"auto, (max-width: 768px) 100vw, 100vw\" srcset=\"data:image\/svg+xml;utf8,&lt;svg%20xmlns=&quot;http:\/\/www.w3.org\/2000\/svg&quot;%20viewBox=&quot;0%200%20820%201224&quot;%20height=&quot;1224px&quot;%20width=&quot;820px&quot;\/&gt;\" data-srcset=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2021\/10\/Phil_Leighton_ligand_BioTech_Pharma_Summit_2021_gallery.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2021\/10\/Phil_Leighton_ligand_BioTech_Pharma_Summit_2021_gallery-201x300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2021\/10\/Phil_Leighton_ligand_BioTech_Pharma_Summit_2021_gallery-686x1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2021\/10\/Phil_Leighton_ligand_BioTech_Pharma_Summit_2021_gallery-768x1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2021\/10\/Phil_Leighton_ligand_BioTech_Pharma_Summit_2021_gallery-630x940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2021\/10\/Phil_Leighton_ligand_BioTech_Pharma_Summit_2021_gallery-420x627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2021\/10\/Phil_Leighton_ligand_BioTech_Pharma_Summit_2021_gallery-315x470.jpg 315w\" \/>\t\t\t\t\t\t\t\n<h3>\n\tTitle: Heavy Chain Only Antibodies to SARS-CoV-2\n\t<\/h3>\n\t<div class=\"su-expand su-expand-collapsed su-expand-link-style-default\" data-height=\"200\"><div class=\"su-expand-content su-u-trim\" style=\"color:#333333;max-height:200px;overflow:hidden\">\n<p>Since the first monoclonal antibody therapy was approved almost forty years ago, the technologies and strategies used in the discovery and expression of immunotherapies have continued to evolve. While the first approved therapies were chimeric proteins or humanized scaffolds, today, transgenic animals dominate discovery platforms. While early therapies derived from mice, today, many different species demonstrate their unique advantages in the field. Because of its phylogenetic distance from humans, the chicken can often generate a superior immune response compared to mice when looking for antibodies to highly conserved proteins. Similarly, camelids express a single domain antibody, a so-called VHH, a heavy chain that does not require a light chain to be co-expressed. The resulting molecule is significantly smaller than an IgG and at an advantage when the targeted epitope is small or partially hidden. We have developed the OmniDAB\u00a9 chicken, a chicken capable of expressing an autonomous heavy chain. These heavy chain only birds mount a robust immune response to a model antigen and display wide epitope coverage. This talk will discuss our recent work using the OmniDAB platform to generate functional, high affinity antibodies to the spike protein of SARS-CoV-2.<\/p>\n<\/div><div class=\"su-expand-link su-expand-link-more\" style=\"text-align:left\"><a href=\"javascript:;\" style=\"color:#0088FF;border-color:#0088FF\"><span style=\"border-color:#0088FF\">Show more<\/span><\/a><\/div><div class=\"su-expand-link su-expand-link-less\" style=\"text-align:left\"><a href=\"javascript:;\" style=\"color:#0088FF;border-color:#0088FF\"><span style=\"border-color:#0088FF\">Show less<\/span><\/a><\/div><\/div>\n<h4>\n\t\t\t<a href=\"#\" title=\"On the Web\" target=\"_self\" rel=\"noopener\">\n\tOn the Web\n\t\t\t<\/a>\n\t<\/h4>\n\t<p><a href=\"https:\/\/www.ligand.com\/\" target=\"_blank\" rel=\"noopener\">https:\/\/www.ligand.com\/<\/a><\/p>\n<h4>\n\t\t\t<a href=\"#\" title=\"On LinkedIn\" target=\"_self\" rel=\"noopener\">\n\tOn LinkedIn\n\t\t\t<\/a>\n\t<\/h4>\n\t<p><a href=\"https:\/\/www.linkedin.com\/in\/phil-leighton-19509989\/\" target=\"_blank\" rel=\"noopener\">Visit Profile<\/a><\/p>\n\n<\/div><!-- .vgblk-rw-wrapper -->","protected":false},"excerpt":{"rendered":"<p>Dr. Philip Leighton Sr. Director, Molecular Biology at Ligand Pharmaceuticals Incorporated Dr. Leighton is Senior Director of Molecular Biology at Ligand Pharmaceuticals in Emeryville, CA.\u00a0 He received his Ph.D in Molecular Biology from Princeton University, followed by post-doctoral studies at the University of California, San Francisco.\u00a0 At Ligand, he is responsible for the development and&#8230;<\/p>\n","protected":false},"author":1,"featured_media":36770,"parent":34722,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"inline_featured_image":false,"footnotes":""},"class_list":["post-36769","page","type-page","status-publish","has-post-thumbnail","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Philip Leighton &#8226; BioTech Pharma Summit<\/title>\n<meta name=\"description\" content=\"Dr. Philip Leighton is Senior Director of Molecular Biology at Ligand Pharmaceuticals in Emeryville, CA. He received his Ph.D in Molecular Biology from Princeton University\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/philip-leighton\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Philip Leighton &#8226; BioTech Pharma Summit\" \/>\n<meta property=\"og:description\" content=\"Dr. Philip Leighton is Senior Director of Molecular Biology at Ligand Pharmaceuticals in Emeryville, CA. He received his Ph.D in Molecular Biology from Princeton University\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/philip-leighton\/\" \/>\n<meta property=\"og:site_name\" content=\"BioTech Pharma Summit\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/biotechpharmasummit\/\" \/>\n<meta property=\"article:modified_time\" content=\"2021-10-26T11:22:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2021\/10\/Phil_Leighton_ligand_BioTech_Pharma_Summit_2021.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"900\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@biotechsummit\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/philip-leighton\/\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/philip-leighton\/\",\"name\":\"Philip Leighton &#8226; BioTech Pharma Summit\",\"isPartOf\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/philip-leighton\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/philip-leighton\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2021\/10\/Phil_Leighton_ligand_BioTech_Pharma_Summit_2021.jpg\",\"datePublished\":\"2021-10-26T11:19:42+00:00\",\"dateModified\":\"2021-10-26T11:22:50+00:00\",\"description\":\"Dr. Philip Leighton is Senior Director of Molecular Biology at Ligand Pharmaceuticals in Emeryville, CA. He received his Ph.D in Molecular Biology from Princeton University\",\"breadcrumb\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/philip-leighton\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/philip-leighton\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/philip-leighton\/#primaryimage\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2021\/10\/Phil_Leighton_ligand_BioTech_Pharma_Summit_2021.jpg\",\"contentUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2021\/10\/Phil_Leighton_ligand_BioTech_Pharma_Summit_2021.jpg\",\"width\":900,\"height\":900,\"caption\":\"Contemporary Headshot and Portrait Studio in Emeryville, CA 1501 Powell St, Suite N, Emeryville, CA | 510-560-5480 info@bayareaheadshotcompany.com San Francisco Bay Area Personal Branding, Business Portraits and Headshots \u00a9 2017 Aida Jones, LLC. All Right Reserved.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/philip-leighton\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.biotechpharmasummit.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Antibody Engineering &#038; Therapeutics 2021 Speakers\",\"item\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Philip Leighton\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#website\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/\",\"name\":\"BioTech Pharma Summit\",\"description\":\"The Tomorrow&#039;s healthcare congress\",\"publisher\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.biotechpharmasummit.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#organization\",\"name\":\"EPM Group\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png\",\"contentUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png\",\"width\":2000,\"height\":2000,\"caption\":\"EPM Group\"},\"image\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/biotechpharmasummit\/\",\"https:\/\/x.com\/biotechsummit\",\"https:\/\/www.instagram.com\/biotechpharmasummit\/\",\"https:\/\/www.linkedin.com\/company\/biotech-pharma-summit\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Philip Leighton &#8226; BioTech Pharma Summit","description":"Dr. Philip Leighton is Senior Director of Molecular Biology at Ligand Pharmaceuticals in Emeryville, CA. He received his Ph.D in Molecular Biology from Princeton University","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/philip-leighton\/","og_locale":"en_US","og_type":"article","og_title":"Philip Leighton &#8226; BioTech Pharma Summit","og_description":"Dr. Philip Leighton is Senior Director of Molecular Biology at Ligand Pharmaceuticals in Emeryville, CA. He received his Ph.D in Molecular Biology from Princeton University","og_url":"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/philip-leighton\/","og_site_name":"BioTech Pharma Summit","article_publisher":"https:\/\/www.facebook.com\/biotechpharmasummit\/","article_modified_time":"2021-10-26T11:22:50+00:00","og_image":[{"width":900,"height":900,"url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2021\/10\/Phil_Leighton_ligand_BioTech_Pharma_Summit_2021.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@biotechsummit","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/philip-leighton\/","url":"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/philip-leighton\/","name":"Philip Leighton &#8226; BioTech Pharma Summit","isPartOf":{"@id":"https:\/\/www.biotechpharmasummit.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/philip-leighton\/#primaryimage"},"image":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/philip-leighton\/#primaryimage"},"thumbnailUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2021\/10\/Phil_Leighton_ligand_BioTech_Pharma_Summit_2021.jpg","datePublished":"2021-10-26T11:19:42+00:00","dateModified":"2021-10-26T11:22:50+00:00","description":"Dr. Philip Leighton is Senior Director of Molecular Biology at Ligand Pharmaceuticals in Emeryville, CA. He received his Ph.D in Molecular Biology from Princeton University","breadcrumb":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/philip-leighton\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/philip-leighton\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/philip-leighton\/#primaryimage","url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2021\/10\/Phil_Leighton_ligand_BioTech_Pharma_Summit_2021.jpg","contentUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2021\/10\/Phil_Leighton_ligand_BioTech_Pharma_Summit_2021.jpg","width":900,"height":900,"caption":"Contemporary Headshot and Portrait Studio in Emeryville, CA 1501 Powell St, Suite N, Emeryville, CA | 510-560-5480 info@bayareaheadshotcompany.com San Francisco Bay Area Personal Branding, Business Portraits and Headshots \u00a9 2017 Aida Jones, LLC. All Right Reserved."},{"@type":"BreadcrumbList","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/philip-leighton\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.biotechpharmasummit.com\/"},{"@type":"ListItem","position":2,"name":"Antibody Engineering &#038; Therapeutics 2021 Speakers","item":"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/"},{"@type":"ListItem","position":3,"name":"Philip Leighton"}]},{"@type":"WebSite","@id":"https:\/\/www.biotechpharmasummit.com\/#website","url":"https:\/\/www.biotechpharmasummit.com\/","name":"BioTech Pharma Summit","description":"The Tomorrow&#039;s healthcare congress","publisher":{"@id":"https:\/\/www.biotechpharmasummit.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.biotechpharmasummit.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.biotechpharmasummit.com\/#organization","name":"EPM Group","url":"https:\/\/www.biotechpharmasummit.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png","contentUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png","width":2000,"height":2000,"caption":"EPM Group"},"image":{"@id":"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/biotechpharmasummit\/","https:\/\/x.com\/biotechsummit","https:\/\/www.instagram.com\/biotechpharmasummit\/","https:\/\/www.linkedin.com\/company\/biotech-pharma-summit\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/36769","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/comments?post=36769"}],"version-history":[{"count":2,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/36769\/revisions"}],"predecessor-version":[{"id":36773,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/36769\/revisions\/36773"}],"up":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/34722"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/media\/36770"}],"wp:attachment":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/media?parent=36769"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}